References
- Huchon G. Lung diseases in the elderly. Respiration 1998; 65: 343–4.
- Eller J, Ede A, Schaberg T, Niedereman MS, Mauch H, Hartmut L. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542–8.
- Woodhead M. Pneumonia in the elderly. J Antimicrob Chemother 1994; 34, Suppl. A: 85–92.
- Macfarlane J. An overview of community-acquired pneumonia with lessons learned from the British Thoracic Society Study. Sem Resp Infect 1994; 9: 153–65.
- Thornsberry C, Ogilvie P, Kahn J, Mauriz Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diag Microbiol Infect Dis 1997; 29: 249–257.
- Jones RN, Pfaller MA, Doern GV. Comparative activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. Diag Microbiol Infect Dis 1998; 32: 119–126.
- Shah PM, Schwärzel R. Bactericidal activity of levofloxacin against Streptococcus pneumoniae in an in-vitro model simulating serum pharmacokinetic parameters. J Antimicrob Chemother 1999; 43, Suppl. C: 71–5.
- Langtry HD, Lamb HM. Levofloxacin. Drugs 1998; 56: 487–515.
- Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994; 38: 738–41.
- Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573–4.
- DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Resp Care 1997; 42: 206–13.
- Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Prac 1998; 7: 101–9.
- Shah PM, Maesen FP, Dolmann A, Vetter N, Fiss E, Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J Antimicrob Chemother 1999; 43: 529–39.
- File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965–72.
- Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski EA. Comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998; 30: 397–404.
- Sato A, Ogawa H, Iwata M, et al. Clinical efficacy of levofloxacin in elderly patients with respiratory tract infections. Drugs; 1995; 42, Suppl. 2: 428–9.
- Wiesinger BA, Kahn JB, Williams RR, Kojak CM, Morgan N. Efficacy of levofloxacin in the treatment of community-acquired pneumonia due to penicillin-resistant Streptococcus pneumoniae. Program and Abstracts of the Sixth International Symposium on New Quinolones, Denver, 1998, Poster S07–13.
- Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Safety 1995; 13: 343–58.